MRKR Marker Therapeutics Inc.

6.82
+0.04  (+1%)
Previous Close 6.78
Open 6.6
Price To Book 341
Market Cap 309428140
Shares 45,370,695
Volume 236,130
Short Ratio
Av. Daily Volume 198,131

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 analysis 1H 2019.
TPIV200
Platinum-sensitive ovarian cancer
Phase 2 interim data due 2H 2018.
TPIV200 + durvalumab
Platinum-sensitive ovarian cancer
Phase 2 enrolment completed late 2017.
TPIV200
Second line triple-negative breast cancer (TNBC)